Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523694 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL522598 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL522597 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL25467327 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL9184430 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL29890793 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21551093 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21551094 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL26077279 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL28390258 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| EP-4308576-B1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| CN-116981674-A | Novel thiazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | GENENTECH, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3980425-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS InnoPharm (Shanghai) Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |
| EP-3901145-A1 | DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE SYNTHESIS OF IMAGING AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3143011-B1 | DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS | HOFFMANN LA ROCHE (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-20200297875-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10675367-B2 | Deuterated compounds and uses thereof | GENENTECH INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190201561-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10076581-B2 | Deuterated compounds and uses thereof | GENENTECH, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20160250358-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | NDUFS3, FOXM1, MT-ND1 | SMN1; SMN2 3031/4885NPC1 582/4885RAB9A 3030/4885 |
| US-20200297875-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | SMN1; SMN2 2211/4885NPC1 232/4885RAB9A 151/4885 |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | SMN1; SMN2 4121/4885NPC1 2062/4885RAB9A 2095/4885 |
| US-10076581-B2 | Deuterated compounds and uses thereof | SLC10A1, AVPR2, SLC9B2 | SMN1; SMN2 2211/4885NPC1 232/4885RAB9A 151/4885 |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | RET, BRAF, ROR1 | SMN1; SMN2 1122/4885NPC1 2603/4885RAB9A 311/4885 |
| US-20190201561-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | SMN1; SMN2 2211/4885NPC1 232/4885RAB9A 151/4885 |
| US-20160250358-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | SMN1; SMN2 2211/4885NPC1 232/4885RAB9A 151/4885 |
| US-10675367-B2 | Deuterated compounds and uses thereof | SLC10A1, AVPR2, SLC9B2 | SMN1; SMN2 2211/4885NPC1 232/4885RAB9A 151/4885 |
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | SLC10A1, SLC9B2, RXFP1 | SMN1; SMN2 1494/4885NPC1 66/4885RAB9A 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.